SHANGHAI, Feb. 10, 2026 — The industry research platform VBData recently spotlighted the “XingShi” Large Language Model (“XS LLM”) from Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a pioneer in AI – driven Internet healthcare solutions, as one of China’s most highly – anticipated healthcare AI models for 2026.
The “XingShi” Large Language Model (“XS LLM”) combines five intelligent agents — knowledge services, triage, pre – consultation, physician support, and electronic medical records — into a closed – loop system that encompasses the entire chronic disease management cycle. This approach has attracted international attention, including coverage by Nature.
As one of the earliest domestic models developed along with the emergence of OpenEvidence, XS LLM is fueled by more than 1.1 million articles from over 170 core journals in the database of the Chinese Medical Association, covering all major clinical disciplines. VBData estimates that the model has provided nearly 400,000 instances of technical assistance to physicians, making it a significant tool for clinical support and professional workflows.
Constructed as the “core digital brain” of Fangzhou’s platform, XS LLM powers five AI – enabled applications: AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI – Powered Search. Each product caters to distinct clinical and patient – side use cases, enabling real – time, precise interventions in areas such as medication guidance, patient education, diagnostic assistance, and medical reference.
XS LLM was previously featured in the Nature News section under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?”. The article delved into the model’s development and included expert opinions on its potential impact on improving chronic disease management.
Other models mentioned by VBData include those from JD Health, Ant Group, and Tencent Health. VBData pointed out that leading domestic medical AI models are being increasingly optimized for China – specific clinical guidelines, reimbursement frameworks, and regulatory requirements to meet the ambitious national goals of broad development of medical AI models by 2027 and near – universal intelligent clinical assistance in primary care by 2030.
Looking forward, Fangzhou will continue to enhance AI integration in chronic disease services, expand access to professional, technology – enabled care, and strengthen its position as a key player in the country’s healthcare digitization drive.
About VBData
Established in 2014, VBData is an industry information accelerator platform that creates a business case library through in – depth analysis, deconstructs sectors via systematic research, and promotes industry collaboration through dedicated services.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in providing customized medical care and AI – enabled precision medicine solutions. For more information, visit .
Media Contact
For further inquiries or interviews, please contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward – looking statements. Actual results may vary significantly from those expected due to various factors. Readers are advised not to overly rely on these statements.
